Search results :

Alfuzosin

More information: STITCH, PubChem and possibly Wikipedia

ATC Code: G04CA01

Side effects

Options: Show MedDRA Preferred Terms

Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7 8 9 10 11 12
Infection 6.13% 3.39% x x
Infestation NOS 6.13% 3.39% x x
Dizziness common, 2.1% - 5.71% 1.3% - 2.8% x x x x x x x x x x x
Stomach ache common x
Asthenia common, 2.1% 1.3% x x x
Abdominal pain common, 1.48% 1.03% x x x x x x x x x x x x
Nausea common, 1.06% 0.59% x x x x x x x x x x x x
Headache common, 1.4% - 2.96% 0.649% - 1.77% x x x x x x x x x x x
Upper respiratory tract infection 1.4% - 6.13% 0.59% - 3.39% x x x x x x x x x x x
Fatigue 1.4% - 2.75% 1.3% - 1.77% x x x x x x x x x x x
Connective tissue disorder 2.11% - 2.2% 2.21% x x
Arthropathy 2.11% 2.21% x x
Influenza-like symptoms 1.9% 2.06% x x
Back pain 1.48% 1.62% x x
Bronchitis 1.48% 0.737% x x x x x x x x x x x
Pain 1.48% 0.59% x x x x x x x x x x x
Erectile dysfunction 1.48% 0.59% x x x x x x x x x x x
Arthralgia 1.4% 1.3% x x x
Calculus of kidney 1.4% x
Pharyngitis 1.4% x x x x x x x x x x x x
Malaise 1.4% x x x
Dyspepsia 1.27% 1.03% x x x x x x x x x x x
Inflicted injury 1.27% 0.442% x x
Constipation 1.06% 0.442% x x x x x x x x x x x
Drowsiness uncommon x
Palpitations uncommon x
Vertigo uncommon x x x
Dry mouth uncommon x
Hypotension uncommon, 0.423% 0% x x x x x x x x x x x
Orthostatic hypotension 0.4% - 2.8% 0% x x x x x x x x x x x
Blood pressure diastolic decreased 0.4% x x x x x x x x x x x
Syncope uncommon — 0.2% - 0.211% 0% x x x x x x x x x x x
Blood pressure systolic decreased 0.2% x
Angina pectoris very rare, postmarketing x x x x x x x x x x x x
Angioedema very rare, postmarketing x x x x x x x x x x x x
Atrial fibrillation very rare, postmarketing x x x x x x x x x
Chest pain postmarketing, uncommon x x x x x x x x x x x x
Diarrhoea postmarketing, uncommon x x x x x x x x x x x x
Oedema postmarketing, uncommon x x x x x x x x
Oedema due to cardiac disease postmarketing x x x x
Toxic epidermal necrolysis postmarketing x x x
Rash postmarketing, uncommon x x x x x x x x x x x x
Flushing postmarketing, uncommon x x x x x x x x x x x x
Gastrointestinal disorder postmarketing x x x x x x x x x x x
Cardiac disorder postmarketing x x x x x x
Jaundice postmarketing x x x x x x x x
Miosis postmarketing x x x x x x x x x
Priapism postmarketing x x x x x x x x x x x
Pruritus postmarketing — 1.4% x x x x x x x x x x x x
Rhinitis postmarketing — 2.1% 1.3% x x x x x x x x x x x x
Tachycardia postmarketing, uncommon x x x x x x x x x x x x
Thrombocytopenia postmarketing x x x x x x x
Urticaria very rare, postmarketing x x x x x x x x x x x x
Angiopathy postmarketing x x x x x x x x x x
Unspecified disorder of skin and subcutaneous tissue postmarketing x x x x x x x x x x
Hepatobiliary disease postmarketing x x x x x x x x x x x
Blood and lymphatic system disorders postmarketing x x x x x x
Intraoperative floppy iris syndrome postmarketing x x x x x x x x x x x x
Coronary artery disease very rare, postmarketing x x x x x x x x x x x
Cholestatic liver injury postmarketing x x x x x x x x
Sweating very rare x
Vomiting very rare x
Arthritis x x
Mental disorder x
Breast disorder x x x
Bursitis x x
Cardiovascular disorder x x x
Eye disorder x x x
Laryngitis x x
Mediastinal disorder x x
Nervous system disorder x x
Neuralgia x x
Neuropathy peripheral x
Sinusitis x x x x x x x x x x x
Torsade de pointes x x
Urinary tract disorder x
Ventricular tachycardia x x
Ventricular arrhythmia x x
Hepatocellular injury x x x
Cardiac fibrillation x x
Arthritis aggravated x x
Neuropathy x x
Ischial neuralgia x x
Lumbar disc lesion x x
Ear and labyrinth disorders x x
Cholestatic liver disease x x x
Change in blood pressure x x x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

AUSTRALIAN APPROVED NAME / XATRAL SR

Side effects:47
Source:medicines.org.au

ALFUZOSIN HYDROCHLORIDE / UROXATRAL

Side effects:26
Source:FDA

ALFUZOSIN

Side effects:39
Source:FDA Structured Product Label

ALFUZOSIN

Side effects:41
Source:FDA Structured Product Label

ALFUZOSIN

Side effects:41
Source:FDA Structured Product Label

ALFUZOSIN

Side effects:42
Source:FDA Structured Product Label

ALFUZOSIN

Side effects:40
Source:FDA Structured Product Label

alfuzosin

Side effects:42
Source:FDA Structured Product Label

ALFUZOSIN

Side effects:42
Source:FDA Structured Product Label

alfuzosin

Side effects:43
Source:FDA Structured Product Label

ALFUZOSIN HYDROCHLORIDE / APO-ALFUZOSIN

Side effects:68
Source:Health Canada

ALFUZOSIN HYDROCHLORIDE / XATRAL

Side effects:68
Source:Health Canada

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label